drugset / Trial / NCT00352417

Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy

NCT00352417 ↗

Phase 2 Completed 50 enrolled Tallikut Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with carotid stenosis scheduled for elective carotid endarterectomy

Timeline

Start
2006-07
Primary completion
2008-07
Completion
2008-07

Outcome

Missed primary endpoint

registry analysis (superiority or other test); VIA-2291 vs Matching Placebo; p = 0.97; t-test, 2 sided NCT00352417 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject ATRELEUTON Small molecule 100 mg Oral

Indications